Medifast, Inc.
NYSE•MED
CEO: Mr. Daniel R. Chard
セクター: Consumer Cyclical
業種: Personal Products & Services
上場日: 1993-12-30
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States and the Asia-Pacific. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. It provides bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups, as well as provides coaching support along with community, nutrition, and healthy habits, and helps people in their weight loss journey. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
連絡先情報
時価総額
$117.72M
PER (TTM)
-6.3
38.9
配当利回り
--
52週高値
$15.46
52週安値
$10.10
52週レンジ
順位19Top 5.6%
6.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$75.10M+0.00%
直近4四半期の推移
EPS
-$1.65+0.00%
直近4四半期の推移
フリーCF
-$6.63M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Drops Significantly Revenue fell 36.0% to $385.8M, driven by 40.6% decline in active earning coaches to 16,100.
Operations Resulted In Loss Income from operations swung to a $14.2M loss, compared to $2.9M income prior period, a 593.8% change.
Coach Productivity Increased Average revenue per active earning coach rose 6.2% to $4,664, reflecting network alignment and focus on productive coaches.
Strategic Transformation Underway Announced holistic metabolic health focus in October 2025, targeting long-term sustainable growth strategy over next decade.
リスク要因
Coach Network Declining Active earning coaches dropped 40.6% year-over-year, threatening future revenue and operating results severely.
Intense GLP-1 Competition Weight loss medications like GLP-1s pose threat, potentially reducing demand for core services and products.
Macroeconomic Spending Pressure Inflation and economic uncertainty could cause consumers to defer or decrease purchases of offerings, impacting results.
Regulatory Scrutiny Continues Direct selling model faces ongoing ambiguity and potential challenges from FTC regarding compensation structures and claims.
見通し
Launching Next-Gen Products Plans to launch new product line in 2026 utilizing Metabolic Synchronization science for metabolic enhancement.
Executing Strategic Pivot Moving from transformation phase to execution phase, focusing on holistic metabolic health advancements and product innovation.
Investing In Coach Tools Continued investment in digital resources and programs like Premier+ to improve coach productivity and client retention.
Capital Allocation Focus Dividend remains discontinued; future capital deployment supports technology and growth initiatives discretionarily.
同業比較
売上高 (TTM)
$1.44B
$1.04B
$725.26M
粗利益率 (最新四半期)
73.5%
69.4%
59.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| DIBS | $208.70M | -15.1 | -14.4% | 14.1% |
| EM | $143.28M | -42.2 | -0.9% | 0.2% |
| BSET | $130.76M | 21.4 | 3.7% | 45.3% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-13.4%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年4月27日
EPS:-$0.12
|売上高:$69.20M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし